By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nabriva Therapeutics 

Leberstrasse 20

Vienna    1112  Austria
Phone: 43-0-1-74093-0 Fax: 43-0-1-74093-1900


SEARCH JOBS








Company News
Nabriva Therapeutics Presents Extended Spectrum Pleuromutilin Antibiotics At The 24th European Congress Of Clinical Microbiology And Infectious Diseases, Barcelona 5/12/2014 12:12:26 PM
Forest Laboratories, Inc. (FRX) Coughs Up $25 Million for Nabriva Therapeutics's Phase II Antibacterial, Right to Take Over Company 6/1/2012 6:42:35 AM
Nabriva Therapeutics Chooses TransPerfect Trial Interactive to Oversee Its Licensing Process 9/27/2011 10:42:28 AM
Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781 9/19/2011 10:33:08 AM
Nabriva Therapeutics Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI 4/18/2011 10:48:33 AM
Nabriva Therapeutics Completes Recruitment for Phase II of Pleuromutilin Antibiotic BC-3781 1/10/2011 10:51:34 AM
Nabriva Therapeutics' Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections with both Oral and IV Dosing in Non-Clinical and Clinical Phase I Studies 9/10/2010 11:35:17 AM
Nabriva Therapeutics Initiates Phase II Of Pleuromutilin Antibiotic BC-3781 6/2/2010 11:32:05 AM
Nabriva Therapeutics Raises $22 Million 10/28/2009 7:25:29 AM
Nabriva Therapeutics Initiates Clinical Phase I Trial of Pleuromutilin Antibiotic BC-3781 7/23/2009 1:45:38 PM
12
//-->